CoChat

Machine Learning in Amyotrophic Lateral Sclerosis: Achievements, Pitfalls, and Future Directions

Open access
Grollemund, Vincent, Pradat, Pierre-François, Querin, Giorgia, Delbot, François, Le Chat, Gaétan, Pradat-Peyre, Jean-François, Bede, Peter · 2019 · Frontiers in Neuroscience
Cited by 152

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Amyotrophic Lateral Sclerosis (ALS) is a relentlessly progressive neurodegenerative condition with limited therapeutic options at present. Survival from symptom onset ranges from three to five years depending on genetic, demographic and phenotypic factors. Despite tireless research efforts, the core aetiology of the disease remains elusive and drug development efforts are confounded by the lack of accurate monitoring markers. Disease heterogeneity, late-stage recruitment into pharmaceutical trials, and inclusion of phenotypically admixed patient cohorts are some of the key barriers to successful clinical trials. Machine Learning (ML) models and large international data sets offer unprecedented opportunities to appraise candidate diagnostic, monitoring and prognostic markers. Accurate patient stratification into well-defined prognostic categories is another aspiration of emerging classification and staging systems Methods The objective of this paper is the comprehensive, systematic and critical review of ML initiatives in ALS to date and their potential in research, clinical and pharmacological applications. The focus of this review is to provide a dual, clinical-mathematical perspective on recent advances and future directions of the field. Another objective of the paper is the frank discussion of the pitfalls and drawbacks of specific models, highlighting the shortcomings of existing studies and to provide methodological recommendations for future study designs. Results Despite considerable sample size limitations, ML techniques have already been successfully applied to ALS data sets and a number of promising diagnosis models have been proposed. Prognostic models have been tested using core clinical variables, biological and neuroimaging data. These models also offer patient stratification opportunities for future clinical trials. Despite the enormous potential of ML in ALS research, statistical assumptions are often violated, the choice of specific statistical models is seldom justified, and the constraints of ML models are rarely enunciated. Conclusions From a mathematical perspective, the main barrier to the development of validated diagnostic, prognostic and monitoring indicators stem from limited sample sizes. The combination of multiple clinical, biofluid and imaging biomarkers is likely to increase the accuracy of mathematical modelling and contribute to optimised clinical trial designs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fnins.2019.00135

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 152

Metadata

Authors
Grollemund, V., Pradat, P.-F., Querin, G., Delbot, F., Le Chat, G., Pradat-Peyre, J.-F., & Bede, P.
Venue
Frontiers in Neuroscience
Published
2019-02-28
Volume
13
Pages
135-135
ISSN
1662-453X (ISSN-L)
OpenAlex
W2918412837
Cited by
152
References
21
FWCI
12.14
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Machine Learning in Amyotrophic Lateral Sclerosis: Achievements, Pitfalls, and Future Directions. https://app.cochat.ai/papers/10.3389/fnins.2019.00135
The paper
Grollemund, V., Pradat, P.-F., Querin, G., Delbot, F., Le Chat, G., Pradat-Peyre, J.-F., & Bede, P. (2019). Machine Learning in Amyotrophic Lateral Sclerosis: Achievements, Pitfalls, and Future Directions. Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2019.00135

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.